Drug-drug interactions and safety assessment between selective Prolyl-tRNA Synthetase inhibitor, DWN12088, and “pirfenidone” or “nintedanib” in healthy subjects
M. Park (Seoul, Republic of Korea), J. Kim (Seoul, Republic of Korea), J. Nam (Seoul, Republic of Korea), J. Choi (Seoul, Republic of Korea), W. Shin (Seongnam, Republic of Korea), H. Yoo (Seongnam, Republic of Korea), A. Kim (Seongnam, Republic of Korea)
Source: International Congress 2022 – Promising new approaches in idiopathic interstitial pneumonias
 
Rating: 
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
M. Park (Seoul, Republic of Korea), J. Kim (Seoul, Republic of Korea), J. Nam (Seoul, Republic of Korea), J. Choi (Seoul, Republic of Korea), W. Shin (Seongnam, Republic of Korea), H. Yoo (Seongnam, Republic of Korea), A. Kim (Seongnam, Republic of Korea). Drug-drug interactions and safety assessment between selective Prolyl-tRNA Synthetase inhibitor, DWN12088, and “pirfenidone” or “nintedanib” in healthy subjects. 1941
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
|
|